Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study - Neuropsychiatrie- Recherche épidémiologique et clinique (U1061) Accéder directement au contenu
Article Dans Une Revue Sleep Année : 2019

Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study

Résumé

STUDY OBJECTIVES: To asses the long-term safety and efficacy of pitolisant, an histamine H3-receptor antagonist, on narcolepsy. METHODS: This open-label, single-arm, pragmatic study, recruited adult patients with narcolepsy and Epworth Sleepiness Scale (ESS) score ≥12. After a titration period, patients were treated for up to 1 year with oral pitolisant once-a-day at up to 40 mg. Concomitant stimulants and anti-cataplectic agents were allowed. The primary endpoint was safety; secondary endpoints included ESS, cataplexy, and other diary parameters. RESULTS: Patients (n = 102, 75 with cataplexy) received pitolisant, for the first time in 73 of them. Sixty-eight patients (51 with cataplexy) completed the 12-month treatment. Common treatment-emergent adverse events were headache (11.8% of patients), insomnia (8.8%), weight gain (7.8%), anxiety (6.9%), depressive symptoms (4.9%), and nausea (4.9%). Seven patients had a serious adverse effect, unrelated to pitolisant except for a possibly related miscarriage. One-third of patients stopped pitolisant, mostly (19.6%) for insufficient benefit. ESS score decreased by 4.6 ± 0.6. Two-thirds of patients completing the treatment were responders (ESS ≤ 10 or ESS decrease ≥ 3), and one third had normalized ESS (≤10). Complete and partial cataplexy, hallucinations, sleep paralysis, and sleep attacks were reduced by 76%, 65%, 54%, 63%, and 27%, respectively. Pitolisant as monotherapy (43% of patients) was better tolerated and more efficacious on ESS than on add-on, but efficacy was maintained in this last case. CONCLUSIONS: Long-term safety and efficacy of pitolisant on daytime sleepiness, cataplexy, hallucinations, and sleep paralysis is confirmed.
Fichier principal
Vignette du fichier
zsz174.pdf (949.37 Ko) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

hal-02559386 , version 1 (27-11-2023)

Licence

Identifiants

Citer

Yves Dauvilliers, Isabelle Arnulf, Zoltan Szakacs, Smaranda Leu-Semenescu, Isabelle Lecomte, et al.. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. Sleep, 2019, 42 (11), ⟨10.1093/sleep/zsz174⟩. ⟨hal-02559386⟩
145 Consultations
26 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More